Known safety concerns, contraindications, and risk factors.
This protocol covers compounds that are not FDA-approved and are prohibited from US pharmacy compounding. Use outside of regulated clinical settings is investigational. The safety data summarised here is drawn primarily from Russian and Eastern European clinical practice; large-scale Western trials do not exist. Do not initiate without medical supervision, and do not source from any channel that cannot provide a current lot-matched certificate of analysis.
Pregnancy or breastfeeding
Use is strictly contraindicated. There is no adequate human safety data on fetal development, placental transfer or neonatal exposure for any peptide in this class. This is a universal exclusion, not a relative contraindication.
Active malignancy or history of cancer
Selank specifically carries a theoretical concern in active or prior malignancy due to its immunomodulatory profile. Semax and Pinealon do not have the same profile but long-term data in cancer survivors is absent. Requires oncology clearance before use.
Active psychotic disorder or severe psychiatric instability
Pinealon is specifically contraindicated in active psychotic disorders or severe psychiatric instability. Selank and Semax have not been studied in these populations; use requires psychiatric supervision.
Uncontrolled hypertension or history of seizures
Semax is used cautiously in these populations. Rare reports of transient blood pressure elevation exist in the clinical literature. Seizure threshold data is limited; until characterised, avoid in active epilepsy or post-seizure populations not on stable anticonvulsant therapy.
Concurrent SSRI, SNRI, MAOI, stimulant or benzodiazepine use
Interaction data is not formally mapped in humans. Semax has been reported to augment psychostimulant effects. SSRI/SNRI interactions are not characterised. Do not combine without clinical supervision; escalate dose slowly if a combination is authorised by a prescriber.